Recommending Drug Combinations Using Reinforcement Learning targeting Genes/proteins associated with Heterozygous Familial Hypercholesterolemia: A comprehensive Systematic Review and Net-work Meta-analysis
Preprint
- 16 February 2023
- preprint
- Published by Springer Nature in Research Square
Abstract
Background: Familial Hypercholesterolemia (FH) is a genetic disorder in lipoprotein metabolism caused by mutations that increase LDL and total cholesterol levels. High LDL and cholesterol levels increase atherosclerosis risk. FH mutations impact the LDL receptor (LDLR) gene, apolipoprotein B, and PCSK9. About 20% of FH cases have a polygenic basis that affects LDL levels. We decided to conduct a systematic review of the available research in this field to provide a thorough genes/proteins network meta-analysis on the impact of drug combinations on the management of heterozygous Familial Hypercholesterolemia (HeFH). This paper reviews and analyzes the literature on the effects of medication combinations on HeFH management. This study investigates articles that analyzed the management and adjuvants of HeFH to recommend forceful drug combinations. Methods: This systematic review and network meta-analysis analyzed the Science Direct, Embase, Scopus, PubMed, Web of Science (ISI), and Google Scholar databases without a lower time limit and up to July 2022. The current study consists of three fundamental stages. Firstly, drug combinations are recommended by reinforcement learning. In the second stage, we used a systematic review to analyze RL's outcomes in diverse populations (with a variety of ages, sex, etc.). Natural Language Processing (NLP) employs context to search these articles. We contrasted manual and NLP-based searches and discovered that NLP could find articles based on MeSH, not simply words. In stage three, we analyze RL outcomes using network meta-analysis. Results: This study uses the RAIN method to investigate the most effective medication combination for managing Heterozygous Familial Hypercholesterolemia (HeFH). Results from the method indicate that the best-recommended scenario is 2.7 times more efficient than the prescription of Ezetimibe as the initial scenario. Conclusion: Our systematic review and network meta-analysis review indicate that a drug combination of Ezetimibe, Pravastatin, and Simvastatin is highly effective. However, additional high-quality clinical trials are required to determine the efficacy and safety of other treatments.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Pharmacogenetic aspects in familial hypercholesterolemia with the special focus on FHMarburg (FH p.W556R)Clinical Research in Cardiology Supplements, 2012
- Clinical characteristics and evaluation of LDL-cholesterol treatment of the Spanish Familial Hypercholesterolemia Longitudinal Cohort Study (SAFEHEART)Lipids in Health and Disease, 2011
- Study of Heart and Renal Protection (SHARP): Randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney diseaseAmerican Heart Journal, 2010
- Heterozygous familial hypercholesterolemia case studyJournal of the American Academy of Nurse Practitioners, 2010
- Baseline cholesterol absorption and the response to ezetimibe/simvastatin therapy: a post-hoc analysis of the ENHANCE trialJournal of Lipid Research, 2010
- Cost-effectiveness analysis of the use of a high-intensity statin compared to a low-intensity statin in the management of patients with familial hypercholesterolaemiaCurrent Medical Research and Opinion, 2009
- TaqIB polymorphism in CETP gene: the influence on incidence of cardiovascular disease in statin-treated patients with familial hypercholesterolemiaEuropean Journal of Human Genetics, 2005
- The contribution of classical risk factors to cardiovascular disease in familial hypercholesterolaemia: data in 2400 patientsJournal of Internal Medicine, 2004
- EzetimibeAmerican Journal of Cardiovascular Drugs, 2003
- Pharmacokinetic-Pharmacodynamic Drug Interactions with HMG-CoA Reductase InhibitorsClinical Pharmacokinetics, 2002